Data-driven to the drug of tomorrow

Opportunities and barriers of AI in a GxP world.
from
  • AI use cases in the pharmaceutical and healthcare industries.
  • The risks and potentials of AI in GxP as well as non-GxP processes.
  • Project report: supported document analysis for targeted identification of adverse drug reactions.

Subscribe to the Merantix Momentum Newsletter now.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

More articles

The latest industry news, interviews, technologies and resources.

Addressing Challenges and Opportunities in Medical Writing Using AI

An interview with Dr. Richardus Vonk, Independent Advisor and Dr. Bertram Weiss, VP Health Vertical at Merantix Momentum.

GenAI for drug discovery

Generative models such as diffusion models have recently gained a lot of attention. Especially conditional generative models show promising approaches to solve complex inverse problems where observations are only indirectly available. This talk will highlight recent advances in generative models and their application to solve inverse problems in drug discovery. In particular, the possible applications and future potential in the field of structure-based drug design will be discussed.

GenAI for drug discovery

Generative models such as diffusion models have recently gained a lot of attention. Especially conditional generative models show promising approaches to solve complex inverse problems where observations are only indirectly available. This talk will highlight recent advances in generative models and their application to solve inverse problems in drug discovery. In particular, the possible applications and future potential in the field of structure-based drug design will be discussed.

How do you make 30 years of data accessible?

In conversation with Jonas Münch, who developed a RAG chatbot at Bayer that combines 30 years of internal data and clinical results in one place.

AI-Driven Compound Optimization in the Large Molecule Space

An expert interview on AI-Driven Compound Optimization in the Large Molecule Space.

Data-driven to the drug of tomorrow

  • AI use cases in the pharmaceutical and healthcare industries.
  • The risks and potentials of AI in GxP as well as non-GxP processes.
  • Project report: supported document analysis for targeted identification of adverse drug reactions.
Oops! Something has gone wrong.
Oops! Something has gone wrong.
Oops! Something has gone wrong.
Oops! Something has gone wrong.
Oops! Something has gone wrong.

Discover more whitepapers

Leveraging the EU AI Act to your advantage

Using the EU AI Act to your advantage

Artificial Intelligence for Private Equity Portfolios

Increase in value for your entire portfolio

The AI Canvas: Our tool for project evaluation

Discover the AI Canvas!

The AI Canvas: Our tool for project evaluation

Discover the AI Canvas!

Leveraging the EU AI Act to your advantage

Using the EU AI Act to your advantage

Artificial Intelligence for Private Equity Portfolios

Increase in value for your entire portfolio
We would like to get to know you!

Start your AI journey with us now

Subscribe now to the Merantix Momentum Newsletter.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.